DK56291A - Anvendelse af gamma-interferon til fremstilling af et laegemiddel til behandling af vasculaer stenosis - Google Patents

Anvendelse af gamma-interferon til fremstilling af et laegemiddel til behandling af vasculaer stenosis Download PDF

Info

Publication number
DK56291A
DK56291A DK056291A DK56291A DK56291A DK 56291 A DK56291 A DK 56291A DK 056291 A DK056291 A DK 056291A DK 56291 A DK56291 A DK 56291A DK 56291 A DK56291 A DK 56291A
Authority
DK
Denmark
Prior art keywords
treatment
medicine
prepare
gamma interferon
vascular stenosis
Prior art date
Application number
DK056291A
Other languages
English (en)
Other versions
DK56291D0 (da
DK174523B1 (da
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Original Assignee
Goeran Hansson
Jan Holm
Lena Jonasson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goeran Hansson, Jan Holm, Lena Jonasson filed Critical Goeran Hansson
Publication of DK56291D0 publication Critical patent/DK56291D0/da
Publication of DK56291A publication Critical patent/DK56291A/da
Application granted granted Critical
Publication of DK174523B1 publication Critical patent/DK174523B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK199100562A 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis DK174523B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
SE8803472 1988-09-30
PCT/SE1989/000520 WO1990003189A1 (en) 1988-09-30 1989-09-27 Use of gamma-interferon for the treatment of vascular stenosis
SE8900520 1989-09-27

Publications (3)

Publication Number Publication Date
DK56291D0 DK56291D0 (da) 1991-03-27
DK56291A true DK56291A (da) 1991-05-24
DK174523B1 DK174523B1 (da) 2003-05-12

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199100562A DK174523B1 (da) 1988-09-30 1991-03-27 Anvendelse af gamma-interferon til fremstilling af et lægemiddel til behandling af vasculær stenosis

Country Status (18)

Country Link
US (1) US5208019A (da)
EP (1) EP0367735B1 (da)
JP (1) JP2895896B2 (da)
KR (1) KR0137017B1 (da)
AT (1) ATE86869T1 (da)
AU (1) AU623181B2 (da)
CA (1) CA1338722C (da)
DD (1) DD288094A5 (da)
DE (1) DE68905438T2 (da)
DK (1) DK174523B1 (da)
HU (1) HU206988B (da)
IE (1) IE63874B1 (da)
IL (1) IL91796A (da)
NZ (1) NZ230816A (da)
PH (1) PH26293A (da)
PT (1) PT91863B (da)
SE (1) SE462364B (da)
WO (1) WO1990003189A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
HU220969B1 (hu) * 1993-01-07 2002-07-29 Thomas Jefferson University A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries PROTECTION FOR ENDOTHEL CELLS
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
ES2314786T3 (es) 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
HUT57063A (en) 1991-11-28
ATE86869T1 (de) 1993-04-15
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
PH26293A (en) 1992-04-10
EP0367735B1 (en) 1993-03-17
JP2895896B2 (ja) 1999-05-24
DE68905438D1 (de) 1993-04-22
SE8803472A (da) 1988-09-30
SE462364B (sv) 1990-06-18
DD288094A5 (de) 1991-03-21
PT91863B (pt) 1995-05-31
DE68905438T2 (de) 1993-09-30
SE8803472D0 (sv) 1988-09-30
DK56291D0 (da) 1991-03-27
NZ230816A (en) 1997-06-24
AU623181B2 (en) 1992-05-07
JPH04500966A (ja) 1992-02-20
US5208019A (en) 1993-05-04
HU895542D0 (en) 1991-10-28
WO1990003189A1 (en) 1990-04-05
CA1338722C (en) 1996-11-19
AU4305189A (en) 1990-04-18
DK174523B1 (da) 2003-05-12
KR0137017B1 (ko) 1998-04-25
EP0367735A1 (en) 1990-05-09
PT91863A (pt) 1990-03-30
IE893123L (en) 1990-03-30
KR900701308A (ko) 1990-12-01
IE63874B1 (en) 1995-06-14
HU206988B (en) 1993-03-01

Similar Documents

Publication Publication Date Title
DK56291D0 (da) Anvendelse af gamma-interferon til fremstilling af et laegemiddel til behandling af vasculaer stenosis
DK486588D0 (da) Konjungater af cytokininer med immunglobuliner
DK0573603T3 (da) Inhibitorer af human neutrofil elastase og human cathepsin G
DK0448765T3 (da) Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
DK399288D0 (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
ATE60329T1 (de) Cumarinderivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung bei der behandlung von krebs.
DK561089A (da) Anvendelse af lactamimider til fremstilling af laegemidler
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DK605589D0 (da) Anvendelse af aminobenzocycloalkaner eller syreadditionssalte deraf til fremstilling af et farmaceutikum, saaledes fremstillet praeparat og dettes anvendelse
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ES2174144T3 (es) Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
FI950010A (fi) Bradykiniiniantagonistien käyttö lääkeaineiden valmistamiseksi virussairauksien hoitamiseksi
DE68906437T2 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti-cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DK0495721T3 (da) Anvendelsen af et polypeptid med en humant-interleukin-2-aktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af pneumothorax
DK72088A (da) Oximethere af 2,6-dioxabicyclo(3.3.0)octanoner og farmaceutiske praeparater til behandling af hjerte- og blodkredsloebssygdomme
IT9041714A0 (it) Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere
DK0625351T3 (da) Anvendelse af etofibrat og farmaceutiske præparater indeholdende etofibrat til behandling af diabetisk angio- og retinopati
RU97119966A (ru) Способ лечения жировой эмболии при переломах длинных трубчатых костей конечностей
RU93045689A (ru) Способ лечения хронической артериальной недостаточности конечностей

Legal Events

Date Code Title Description
PUP Patent expired